Global Acute Myeloid Leukemia (AML) Market Report 2026-2036 | Forecast to Reach USD 11.81 Billion as Menin Inhibitors and Precision Therapies Drive 9.2% CAGR
Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Acute Myeloid Leukemia Market Size, Share, Forecast & Trends Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global acute myeloid leukemia (AML) market was valued at USD 4.35 billion in 2025 and is estimated to reach USD 4.90 billion in 2026. Revenue is forecast to increase to USD 11.81 billion by 2036, representing a CAGR of 9.2% during the 2026-2036 forecast period. The report examines AML epidemiology, molecular subtypes, treatment pathways, measurable residual disease (MRD) testing, diagnostics, drug pipelines, pricing, reimbursement, regulation, and competitive positioning.
The market encompasses therapies used across induction, consolidation, maintenance, and relapsed or refractory settings. Major categories include targeted therapy, injectable and oral hypomethylating agents, cytotoxic chemotherapy, antibody-drug conjugates, immunotherapies, cell and gene therapy, and supportive care. Targeted products include menin inhibitors, the BCL-2 inhibitor venetoclax, FLT3 inhibitors, IDH inhibitors, and hedgehog pathway inhibitors.
AML disease burden and treatment demand
AML continues to be associated with substantial morbidity and mortality, particularly among older adults. According to the National Cancer Institute's SEER program, the median age at diagnosis is 70 years, approximately 62% of cases occur in people aged 65 or older, and five-year relative survival is 33.4%. An estimated 22,720 new U.S. cases and 11,500 deaths are expected in 2026. Globally, the International Agency for Research on Cancer recorded 495,113 new leukemia cases in 2022, with nearly half occurring in Asia.
Venetoclax-based treatment remains a major source of market spending. AbbVie reported worldwide Venclexta sales of USD 2.79 billion in 2025, including revenue from chronic lymphocytic leukemia. Venetoclax combined with azacitidine or low-dose cytarabine has become an established treatment for patients ineligible for intensive chemotherapy and is increasingly used as a foundation for combination regimens.
Market growth drivers and emerging opportunities
The introduction of menin inhibitors is a leading acute myeloid leukemia market growth driver. The U.S. FDA approved Kura Oncology and Kyowa Kirin's ziftomenib (KOMZIFTI) on 13 November 2025, following the approval of Syndax's revumenib (Revuforj). These approvals established two commercial products in the class within approximately one year. Wider molecular sequencing at diagnosis, an aging population, and regulatory acceptance of single-arm clinical evidence are also supporting market expansion.
The largest commercial opportunity is expected to come from moving menin inhibitors into frontline combinations. The Phase 3 KOMET-017 study is evaluating ziftomenib in newly diagnosed patients, while revumenib is being studied with azacitidine and venetoclax in untreated AML with NPM1 or KMT2A alterations. Additional opportunities include MRD-guided treatment, maintenance therapy, post-transplant use, all-oral regimens, outpatient delivery, and expansion in markets where molecular diagnostics and reimbursement are improving.
Market constraints include small molecularly defined patient populations, limited treatment duration, early mortality, drug resistance, and toxicity in frail patients. Generic cytarabine, anthracyclines, azacitidine, and decitabine also limit revenue from regimen backbones. Payer scrutiny remains significant for high-cost therapies with modest response rates, while limited sequencing and transplant capacity restrict targeted drug adoption across parts of Asia, Africa, and Latin America.
Acute myeloid leukemia market segment outlook
- Therapy class: Targeted therapy is expected to hold the largest market share in 2026, supported by venetoclax, FLT3 inhibitors, IDH1 and IDH2 inhibitors, and menin inhibitors. Menin inhibitors are forecast to record the highest CAGR as recently approved products advance into frontline trials.
- Mutation target: Mutation-agnostic and broad-spectrum regimens are projected to lead in 2026 because venetoclax-based combinations and chemotherapy remain widely used. NPM1-mutated AML is expected to grow fastest as menin inhibitor indications and frontline development expand the eligible population.
- Line of therapy: Frontline induction and consolidation are expected to generate the largest share. Maintenance therapy is forecast to grow at the highest CAGR, supported by oral hypomethylating agents, targeted post-remission strategies, post-transplant treatment, and MRD-based risk assessment.
- Patient fitness: Patients ineligible for intensive chemotherapy are expected to represent the largest segment due to the older AML population and the prevalence of comorbidities. The intensive chemotherapy-eligible segment is projected to grow rapidly as targeted drugs are incorporated into induction, consolidation, and post-transplant regimens.
- Route of administration: Oral therapy is expected to lead and record the highest CAGR. Growth is supported by venetoclax, FLT3 and IDH inhibitors, menin inhibitors, and oral hypomethylating products.
- Treatment setting: Outpatient and ambulatory care is projected to hold the largest share in 2026. Home-based care is expected to grow fastest as all-oral regimens, specialty pharmacy services, remote toxicity monitoring, and telehealth become more widely used.
- End user: Hospitals and academic cancer centers are expected to remain the leading segment, while specialty hematology and community oncology practices are forecast to grow rapidly as lower-intensity regimens and molecular testing become more accessible.
Regional market outlook
North America is expected to hold the largest acute myeloid leukemia market share in 2026. The region benefits from early regulatory access, broad molecular testing, extensive transplant capacity, and high spending per patient. Both approved menin inhibitors were initially launched in the U.S.
Europe is projected to remain the second-largest regional market, supported by academic hematology networks, cooperative clinical trial groups, and established transplant infrastructure. Uptake can be moderated by health technology assessment requirements and comparisons with low-cost generic treatments. Germany, the U.K., France, Italy, and Spain account for most regional value.
Asia-Pacific is forecast to grow at the highest CAGR through 2036. Expansion is supported by a large disease burden, improving molecular testing, targeted drug inclusion in reimbursement programs, volume-based procurement, and increased transplant capacity. Japan remains the region's most developed market, while China combines a large patient population with active domestic development of menin, FLT3, and BCL-2 inhibitors.
Brazil leads the Latin American market, followed by Mexico, Argentina, and Colombia, although diagnostic access remains a barrier. In the Middle East & Africa, Gulf states, Israel, and Turkey are adopting innovative therapies more rapidly, while limited diagnostic capacity continues to restrict treatment access in much of Sub-Saharan Africa.
Competitive landscape
The AML market is moderately consolidated, combining multinational pharmaceutical companies with specialist developers and generic drug suppliers. AbbVie and Roche hold venetoclax, while Astellas, Novartis, and Daiichi Sankyo compete in FLT3-targeted treatment. Servier and Rigel participate in the IDH inhibitor segment, and Bristol Myers Squibb, Otsuka, and Taiho market oral hypomethylating products. Pfizer markets an antibody-drug conjugate, Jazz Pharmaceuticals supplies liposomal chemotherapy, and Syndax, Kura Oncology, and Kyowa Kirin lead the commercial menin inhibitor class.
Johnson & Johnson and Sumitomo Pharma are developing additional menin inhibitors. Teva, Sandoz, Dr. Reddy's, and Hikma remain important suppliers of generic AML treatment backbones. Competition is being shaped by regulatory approvals, label expansions, licensing agreements, regional partnerships, companion diagnostic collaborations, acquisitions, and frontline clinical trial results.
Strategic value of the report
- Provides global AML market estimates and forecasts through 2036.
- Evaluates menin inhibitors, venetoclax-based regimens, molecular diagnostics, and MRD testing.
- Identifies high-growth opportunities by therapy class, mutation target, treatment line, patient fitness, administration route, care setting, end user, and region.
- Assesses pricing, reimbursement, generic competition, resistance, toxicity, and patient access barriers.
- Tracks frontline, maintenance, relapsed or refractory, immunotherapy, and cell therapy pipelines.
- Benchmarks leading pharmaceutical companies, specialist developers, and generic suppliers.
- Supports portfolio planning, clinical development, market access, investment, partnership, and licensing decisions.
For more information about this report visit https://www.researchandmarkets.com/r/n0669i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

